Vascular endothelial growth factor
327
MENTIONS
81
EPISODES
69
PODCASTS
Search complete. 327 mentions across 81 episodes found for "Vascular endothelial growth factor".
Oct 29, 2026
Nadia WaheedGUEST
The fluid or blood causes a decline in vision and and then eventually causes scarring and a further decline in vision over time if it is left untreated.
Megan HallHOST
And so to combat this problem, scientists developed these injections of anti-vascular endothelial growth factor.
Megan HallHOST
Most people just call it anti-VEGF treatments.
Megan HallHOST
And they stop those abnormal blood vessels from growing.
Megan HallHOST
So tell me a little bit about how effective these medications are at slowing down that damage in the eye.
Nadia WaheedGUEST
So if taken early and if used consistently, these medications are effective.
Nadia WaheedGUEST
They've been an absolute breakthrough because they can stop further vision loss and they may help improve vision for many of our patients.
Nadia WaheedGUEST
However, the issue is the long-term use of these agents because the long-term use of anti-VEGF for wet AMD, if you look at study after study after study that look at how these medications do in patients over time, They're associated with visual acuity declining over time.
Don D'AmicoGUEST
Delighted to be here.
Scott KriswanasHOST
Now, remind our listeners about the efficacy ceiling currently faced with anti-VEGF agents for DME therapy.
Don D'AmicoGUEST
Anti-VEGF therapy for DME has been remarkably effective And it certainly was a major, major advance.
Don D'AmicoGUEST
But still, based on many studies, some 40% of patients either have an incomplete response, an impermanent response, and will relapse and have persistent fluid, et cetera.
Don D'AmicoGUEST
And so there's clearly room.
Don D'AmicoGUEST
as an unmet need for additional therapies.
Don D'AmicoGUEST
Nevertheless, we're delighted to have anti-VEGF agents compared to what we had previously, which was simply, you know, grid laser treatment and perhaps some judicious use of intravitreal steroids.
Scott KriswanasHOST
And where does the Wnt pathway fit into all of this?
Amy SkiltonHOST
Yes, yes.
Amy SkiltonHOST
I mean, certainly in the animal studies, I found the NRF2 signaling really interesting, the influence on inflammatory cytokines and also VEGF and tissue repair.
Amy SkiltonHOST
And I think it'll be, yeah, it'll be really helpful if we can elucidate whether or not that's what's happening in humans as well.
Amy SkiltonHOST
But speaking more of the local tissues, there are also studies using C. buckthorn, not just orally, but intravaginally as well.
Anshul GuptaHOST
One of the processes involved is angiogenesis, which means the formation of new blood vessels.
Anshul GuptaHOST
Experimental research has investigated BPC-157's effects on pathways involved in vascular function, including VEGF-related signaling, nitric oxide signaling, and the AKTENOS pathway.
Anshul GuptaHOST
These pathways participate in endothelial cell function, blood vessel behavior, and tissue repair.
Anshul GuptaHOST
Researchers have also investigated its effects on cellular survival and other repair-related processes.
Mike BelkowskiHOST
It's that animal research suggests it interacts with several pathways involved in how tissues respond to damage.
Mike BelkowskiHOST
These include VEGF signaling involving angiogenesis, endothelial function and nitric oxide signaling pathways, extracellular matrix remodeling, inflammatory signaling, and several gene networks associated with tissue repair.
Mike BelkowskiHOST
So rather than thinking of BPC-157 as a construction crew magically rebuilding damaged tissue, I think a better way to conceptualize it is as a potential coordinator of the tissue repair environment.
Mike BelkowskiHOST
And that becomes particularly interesting when we start talking about the nervous system because there are several surprisingly interesting preclinical studies involving BPC-157 and neurological injury.
Mike BelkowskiHOST
In one study, researchers temporarily clamped the carotid arteries and then restored blood flow.
Mike BelkowskiHOST
BPC-157 treatment was associated with reduced hippocampal neuronal injury along with recovery in memory, locomotor function, and coordination.
Mike BelkowskiHOST
Researchers also observed changes in genes associated with VEGF receptor signaling, nitric oxide synthesis, inflammatory signaling, and stress responses.
Mike BelkowskiHOST
Again, this is preclinical, but notice the recurring theme.
Jack CliffordGUEST
And that's a dynamic thing based on what you're doing and where the blood needs to go.
Jack CliffordGUEST
But as nitric oxide is being released, there's this whole downstream chemical cascade that happens that ends up with a lot of things, one of which is VEGF, or vascular endothelial growth factor.
Jack CliffordGUEST
And so you end up with a lot of... angiogenesis going on throughout your body where you need it at these pressure differentials at the places in your in your pipes if you will where your body senses that you know it's getting too much shear stress and so it has to grow you know so so you'll see they give it like a root system you know because that's really what it looks like if you were to if you could image it it's really difficult to image it through standard imaging techniques but anyhow um so like i'm 100 blocked here you know this is my widowmaker artery right this that that left anterior descending it's 100 blocked my my uh left is 95 and my right is 80. and nothing's changed this is five years it's been like this right well documented but i can run a sub seven mile right now I can do that because I've grown around all of my blockages with much smaller vessels like the root system, right? But the total volume more than makes up for what's blocked.
Jack CliffordGUEST
And so I have no issues, but I've had no stents.
Joanie JacksonGUEST
We see their LDH improve.
Joanie JacksonGUEST
We see if there's other imbalances in the body, things like the fibrinogen level and things like the different growth factors, your VEGF, a lot of that can be improved.
Joanie JacksonGUEST
And even though there's not as many studies that support heavy metals and things like that being removed.
Joanie JacksonGUEST
I have had patients, again, we know that we live in such a toxic world with a toxic soup of chemicals that we're exposed to each and every day.
Tahamtan AhmadiGUEST
And, again, bispecificity then falls into buckets.
Tahamtan AhmadiGUEST
One is, broadly speaking, the T-cell redirection, and the other one is trying to impact two different targets that are on the tumor, either the way we do it with Pitazomib, we'll get to that part later on, or Amivantamab, which is the J&J drug that came out of Gemma Discovery, now commercializes VibraVent, or on the also very exciting emerging space on dual blockade PD-1, PD-1 VEGF combos.
Tahamtan AhmadiGUEST
So as the robustness of bispecificities was more appreciated, I think then there was also now a plethora of different bispecific platforms, and today now bispecificity is I cannot even count the number of different platforms that exist.
Tahamtan AhmadiGUEST
Broadly speaking, the principles have been unlocked and then there's multiple roads to that.
Harry ColasGUEST
So much of the healthcare costs in our system today are really late in life, right? We don't identify and treat diseases until the symptoms actually show up.
Harry ColasGUEST
If we think about things like a wet AM day, You get to the retina specialist when you're already wet, and then you go through anti-VEGF.
Harry ColasGUEST
Well, what if we found diseases way earlier in life? And then we get those patients to care and get them on treatment earlier to help stave off the progression of that disease as far as humanly possible, and that should drive down overall healthcare costs in the future.
Harry ColasGUEST
We're on the cusp of that happening.
Ken BerryHOST
of component factor H and they still have a minuscule risk and a minuscule rate of incidence of macular degeneration.
Ken BerryHOST
So what's going on here? If it's not age, if it's not genetics, if it's not our technology getting better, then what's going on and we have to all just stop and think have have we evolved since 1910 since 1890 have our genetics changed so much in 100 120 130 years that now we are susceptible to macular degeneration at such a rate that it's considered an epidemic Most, the average ophthalmologist today spends the majority of his or her time in clinic injecting retinas with Avastin and other things, other VEGF inhibitors, trying to keep wet macular degeneration from getting worse, or trying to prevent dry macular degeneration from coming wet macular degeneration, which is the worst kind.
Ken BerryHOST
But what's going on? So when you look at the population data, you find that in populations that eat the most processed food, yep, you thought I'd get around to that? Well, here it is.
Ken BerryHOST
But surprisingly, it doesn't look like it's the sugars and it doesn't look like it's the grains.
71 more episodes mention Vascular endothelial growth factor.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.